Investor FAQ
Common questions about investing in ScreenND™
What problem does ScreenND™ solve?
ScreenND™ addresses the critical gap in accessible, standardised pre-diagnostic screening for children. Current processes are fragmented, inconsistent, and time-consuming, leading to delayed assessments and missed opportunities for early identification.
What is the market opportunity?
The global paediatric healthcare market is valued at over £200 billion, with rising demand for digital health solutions. In the UK alone, more than 12 million children could benefit from improved screening processes, representing a significant addressable market.
How does SEIS work?
The first £250k of our raise qualifies for SEIS (Seed Enterprise Investment Scheme). This provides UK investors with up to 50% income tax relief, alongside additional benefits including capital gains tax exemption and loss relief provisions. We also welcome investment from international investors outside of SEIS.
What is your business model?
We operate a B2B2C SaaS model. Our platform will be licensed by schools, local authorities, and healthcare providers, ensuring recurring revenue while maintaining clinical oversight and quality assurance.
What makes your technology unique?
Our platform will uniquely combine NICE-aligned clinical protocols with age-appropriate interfaces and multi-informant data collection. This ensures clinical accuracy while remaining accessible for parents, educators, and clinicians.
What is the minimum funding required to succeed?
We are seeking to raise £500k. This will allow full-time and dedicated focus on the project. If we were to raise less, we could scale the MVP accordingly and demonstrate proof of concept, but would need to raise additional funds sooner.
How long will £500k last?
We forecast an 18-month runway with £500k, covering founder time, product development, clinical validation, pilot programmes, and early traction.
What equity are you offering at pre-seed?
Our aim is to raise £500k while limiting dilution to a maximum of 15%. This values ScreenND™ at around £3–3.5m pre-seed, which we believe is reasonable given the market size, clinical need, and barriers to entry.
What are the biggest risks, and how will you mitigate them?
The main risks are trust and clinical adoption. We are not diagnosing, but digitising respected screening tools aligned with NICE guidance. Risk is mitigated through establishing an Advisory Board, engaging schools, and ensuring transparent multi-informant processes.
What prevents competitors from moving faster?
This is not a simple space to navigate. Our lived experience, early groundwork, and commitment to compliance and NICE alignment give us a strong position. With investment, we are well placed to move quickly and credibly.
How will you manage data security and regulation?
All development will be built on GDPR and safeguarding compliance from day one. While we are not yet processing data, our foundations are designed to ensure user trust, transparency, and regulatory alignment.
Who will pay for this?
Our initial focus is on empowering parents to start the process directly. Over time, we plan to integrate with the NHS and schools so ScreenND™ becomes the trusted pre-diagnostic tool that saves both time and money. Internationally, we see opportunities for licensing to different healthcare systems.
How will you drive adoption?
Families face long waits and often experience stigma or blame. By providing trusted, NICE-aligned screening with clear reporting, ScreenND™ empowers families and removes barriers. Schools and clinicians benefit from consistent, validated insights.
How will you overcome clinician scepticism?
We will work with advisors and ensure our tools are digitised versions of established protocols. Being sceptical of ScreenND™ would be equivalent to being sceptical of the existing tools — our platform makes them more consistent, transparent, and accessible.
Why are you the right person to lead this?
I have lived experience as both a parent of a neurodivergent child and a late-diagnosed autistic/ADHD adult. I know the system, its flaws, and its impact. Professionally, my background is in recruitment, which has given me the ability to build teams and bring the right skills together. I am committed to delivering this change and will not do it alone — building the right team and advisory support is a top priority.
Do you have advisors or partnerships already?
Not yet. Securing an Advisory Board is a priority immediately after funding, focused on clinical expertise, regulatory assurance, and NHS engagement.
What impact will you achieve in the first year?
In year one we will demonstrate that our product works and can scale. We expect to move beyond MVP, run pilot programmes, and establish partnerships that set the foundation for licensing and wider adoption.
What is your long-term vision?
Our goal is to transform referral pathways in the UK and then expand globally. Potential outcomes include NHS adoption, international licensing, and partnerships with larger healthtech or EdTech players.
What is the exit opportunity for investors?
Under SEIS and EIS, investors should not expect guaranteed returns — these schemes exist to support high-risk early-stage companies. However, if ScreenND™ achieves its vision, multiple exit routes will be possible. These could include acquisition by a healthcare or technology platform, licensing and international partnerships, or future growth funding rounds leading to liquidity events. My commitment is to deliver meaningful change. If we succeed, that change will naturally create opportunities for investors to realise value.